Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 31

Adult ID

HIV-STD-TB
Symposium

84 - Long-acting ART

Friday, October 1, 2021
11:30 AM - 12:45 PM EDT

    Moderator(s)

  • VT

    Virginia Triant, MD, MPH

    Assistant Professor
    MGH
    Boston, MA, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Allison Agwu, MD, MSc

    Professor
    Johns Hopkins University
    Baltimore, MD, United States

    Gilead (Individual(s) Involved: Self): Other Financial or Material Support, scientific advisor, Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Scientific Research Study Investigator

    • Speaker(s)

  • Lauren Collins, MD, MSc

    Assistant Professor of Medicine
    Medicine
    Division of Infectious Diseases, Emory University School of Medicine
    Atlanta, Georgia, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • David Wohl, MD

    Professor of Medicine
    UNC School of Medicine
    Chapel Hill, NC, United States

    Gilead Sciences (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Research Grant or Support, Scientific Research Study Investigator; Janssen (Individual(s) Involved: Self): Advisor or Review Panel member; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support; ViiV (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support

Participants should be aware of the following financial/non-financial relationships:
Virginia A. Triant, MD, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Allison Agwu, MD, MSc: Gilead (Individual(s) Involved: Self): Other Financial or Material Support, scientific advisor, Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Scientific Research Study Investigator
Lauren F. Collins, MD, MSc: I do not have any relevant financial / non-financial relationships with any proprietary interests.
David Alain Wohl, MD: Gilead Sciences (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Research Grant or Support, Scientific Research Study Investigator; Janssen (Individual(s) Involved: Self): Advisor or Review Panel member; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support; ViiV (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • discuss the indications and use of currently-available long-acting antiretroviral therapy
  • identify the new antiretrovirals under development as long-acting therapies
  • recognize the barriers to implementation of long-acting antiretroviral therapy and strategies to address them

Presentations:

  • Implementation of Long-acting ART in the Real World

    Speaker: Lauren F. Collins, MD, MSc – Division of Infectious Diseases, Emory University School of Medicine

  • Long Acting Agents to Treat HIV: Available Agents and Future Landscape

    Speaker: David Alain Wohl, MD – UNC School of Medicine